全文获取类型
收费全文 | 50604篇 |
免费 | 5594篇 |
国内免费 | 3385篇 |
专业分类
耳鼻咽喉 | 611篇 |
儿科学 | 625篇 |
妇产科学 | 643篇 |
基础医学 | 5272篇 |
口腔科学 | 1210篇 |
临床医学 | 6088篇 |
内科学 | 7015篇 |
皮肤病学 | 623篇 |
神经病学 | 2518篇 |
特种医学 | 1969篇 |
外国民族医学 | 14篇 |
外科学 | 6429篇 |
综合类 | 9110篇 |
现状与发展 | 15篇 |
一般理论 | 3篇 |
预防医学 | 3787篇 |
眼科学 | 1205篇 |
药学 | 5491篇 |
40篇 | |
中国医学 | 3037篇 |
肿瘤学 | 3878篇 |
出版年
2024年 | 227篇 |
2023年 | 1002篇 |
2022年 | 2331篇 |
2021年 | 2915篇 |
2020年 | 2278篇 |
2019年 | 1896篇 |
2018年 | 1948篇 |
2017年 | 1846篇 |
2016年 | 1670篇 |
2015年 | 2541篇 |
2014年 | 3037篇 |
2013年 | 3146篇 |
2012年 | 4125篇 |
2011年 | 4438篇 |
2010年 | 3230篇 |
2009年 | 2585篇 |
2008年 | 2967篇 |
2007年 | 2897篇 |
2006年 | 2597篇 |
2005年 | 2372篇 |
2004年 | 1676篇 |
2003年 | 1384篇 |
2002年 | 1185篇 |
2001年 | 862篇 |
2000年 | 778篇 |
1999年 | 723篇 |
1998年 | 379篇 |
1997年 | 385篇 |
1996年 | 316篇 |
1995年 | 254篇 |
1994年 | 235篇 |
1993年 | 154篇 |
1992年 | 175篇 |
1991年 | 180篇 |
1990年 | 168篇 |
1989年 | 135篇 |
1988年 | 114篇 |
1987年 | 85篇 |
1986年 | 67篇 |
1985年 | 36篇 |
1984年 | 41篇 |
1983年 | 18篇 |
1982年 | 20篇 |
1981年 | 23篇 |
1980年 | 15篇 |
1979年 | 18篇 |
1978年 | 19篇 |
1977年 | 18篇 |
1975年 | 10篇 |
1974年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention 下载免费PDF全文
5.
中风病是临床的常见病、多发病。本病病因较多,病情变化迅速,证型繁杂,不同的文献中证候分类差异较大。证候分类的繁杂给临床工作者治疗中风病带来极大不便。本文对以证候要素(内风、内火、痰湿、瘀血、气虚、阴虚)为切入点论治中风病的理论进行探讨,并举例论证其临床疗效。 相似文献
6.
阳昊廖宁李小珍 《中国卫生质量管理》2020,(6):147-150
探索一套符合现代化医院的行政总值班管理体系,确保医院管理工作安全、稳定运行。分析国内外医院总值班现状和问题,运用系统性、科学性、规范性等综合干预措施,进一步提高值班人员责任意识、分析问题和解决问题能力等综合管理能力,使总值班管理从粗放式向精细化转变,实现目标标准化、过程规范化、结果同质化的服务格局。 相似文献
7.
Jae Eun Choi Tyler Werbel Zhenping Wang Chia Chi Wu Tony L. Yaksh Anna Di Nardo 《Journal of dermatological science》2019,93(1):58-64
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献8.
Xue Yao Yan Zhang Jian Hao Hui-Quan Duan Chen-Xi Zhao Chao Sun Bo Li Bao-You Fan Xu Wang Wen-Xiang Li Xuan-Hao Fu Yong Hu Chang Liu Xiao-Hong Kong Shi-Qing Feng 《中国神经再生研究》2019,(3)
Ferroptosis is an iron-dependent novel cell death pathway. Deferoxamine, a ferroptosis inhibitor, has been reported to promote spinal cord injury repair. It has yet to be clarified whether ferroptosis inhibition represents the mechanism of action of Deferoxamine on spinal cord injury recovery. A rat model of Deferoxamine at thoracic 10 segment was established using a modified Allen's method. Ninety 8-week-old female Wistar rats were used. Rats in the Deferoxamine group were intraperitoneally injected with 100 mg/kg Deferoxamine 30 minutes before injury. Simultaneously, the Sham and Deferoxamine groups served as controls. Drug administration was conducted for 7 consecutive days. The results were as follows:(1) Electron microscopy revealed shrunken mitochondria in the spinal cord injury group.(2) The Basso, Beattie and Bresnahan locomotor rating score showed that recovery of the hindlimb was remarkably better in the Deferoxamine group than in the spinal cord injury group.(3) The iron concentration was lower in the Deferoxamine group than in the spinal cord injury group after injury.(4) Western blot assay revealed that, compared with the spinal cord injury group, GPX4, xCT, and glutathione expression was markedly increased in the Deferoxamine group.(5) Real-time polymerase chain reaction revealed that, compared with the Deferoxamine group, mRNA levels of ferroptosis-related genes Acyl-CoA synthetase family member 2(ACSF2) and iron-responsive element-binding protein 2(IREB2) were up-regulated in the Deferoxamine group.(6) Deferoxamine increased survival of neurons and inhibited gliosis. These findings confirm that Deferoxamine can repair spinal cord injury by inhibiting ferroptosis. Targeting ferroptosis is therefore a promising therapeutic approach for spinal cord injury. 相似文献
9.
Fur-Hsing Wen Jen-Shi Chen Wen-Chi Chou Wen-Cheng Chang Wen Chi Shen Chia-Hsun Hsieh Siew Tzuh Tang 《Journal of pain and symptom management》2019,57(1):64-72
Context
Family caregivers constitute a critical component of the end-of-life care system with considerable cost to themselves. However, the joint association of terminally ill cancer patients' symptom distress and functional impairment with caregivers' subjective caregiving burden, quality of life (QOL), and depressive symptoms remains unknown.Objectives/Methods
We used multivariate hierarchical linear modeling to simultaneously evaluate associations between five distinct patterns of conjoint symptom distress and functional impairment (symptom-functional states) and subjective caregiving burden, QOL, and depressive symptoms in a convenience sample of 215 family caregiver–patient dyads. Data were collected every 2 to 4 weeks over patients' last 6 months.Results
Caregivers of patients in the worst symptom-functional states (States 3–5) reported worse subjective caregiving burden and depressive symptoms than those in the best two states, but the three outcomes did not differ between caregivers of patients in State 3 and States 4–5. Caregivers of patients in State 5 endured worse subjective caregiving burden and QOL than those in State 4. Caregivers of patients in State 4 suffered worse subjective caregiving burden and depressive symptoms but comparable QOL to those in State 2.Conclusion
Patients' five distinct, conjoint symptom-functional states were significantly and differentially associated with their caregivers' worse subjective caregiving burden, QOL, and depressive symptoms while caring for patients over their last 6 months. 相似文献10.